While inhibition or blockade of MDK signaling may be a promising option for neoplastic, inflammatory, or autoimmune diseases affecting the CNS, endogenous or exogenous increase of MDK levels could improve the outcome in the context of acute CNS injuries and ischemia. This evidence concerns the gene MDK and autoimmune disease.